2980 related articles for article (PubMed ID: 25141367)
21. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review.
Balk EM; Adams GP; Langberg V; Halladay C; Chung M; Lin L; Robertson S; Yip A; Steele D; Smith BT; Lau J; Lichtenstein AH; Trikalinos TA
Evid Rep Technol Assess (Full Rep); 2016 Aug; (223):1-1252. PubMed ID: 30307737
[TBL] [Abstract][Full Text] [Related]
22. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia.
Ogier N; Amiot MJ; Georgé S; Maillot M; Mallmann C; Maraninchi M; Morange S; Lescuyer JF; Peltier SL; Cardinault N
Eur J Nutr; 2013 Mar; 52(2):547-57. PubMed ID: 22527287
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
24. ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia.
Kasliwal RR; Bansal M; Gupta R; Shah S; Dani S; Oomman A; Pai V; Prasad GM; Singhvi S; Patel J; Sivam S; Trehan N
Nutrition; 2016; 32(7-8):767-76. PubMed ID: 27143594
[TBL] [Abstract][Full Text] [Related]
25. Dietary fat intake, body composition and blood lipids of university men and women.
Neville MM; Geppert J; Min Y; Grimble G; Crawford MA; Ghebremeskel K
Nutr Health; 2012 Jul; 21(3):173-85. PubMed ID: 23533205
[TBL] [Abstract][Full Text] [Related]
26. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
27. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia.
Pirillo A; Catapano AL
Int J Cardiol; 2013 Dec; 170(2 Suppl 1):S16-20. PubMed ID: 23856442
[TBL] [Abstract][Full Text] [Related]
28. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
Harris WS; Dayspring TD; Moran TJ
Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
[TBL] [Abstract][Full Text] [Related]
29. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
30. Small supplements of N-3 fatty acids change serum low density lipoprotein composition by decreasing phospholid and apolipoprotein B concentrations in young adult women.
Sanchez-Muniz FJ; Bastida S; Viejo JM; Terpstra AH
Eur J Nutr; 1999 Feb; 38(1):20-7. PubMed ID: 10338684
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients.
Marazzi G; Cacciotti L; Pelliccia F; Iaia L; Volterrani M; Caminiti G; Sposato B; Massaro R; Grieco F; Rosano G
Adv Ther; 2011 Dec; 28(12):1105-13. PubMed ID: 22113535
[TBL] [Abstract][Full Text] [Related]
32. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
33. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention.
Heinz T; Schuchardt JP; Möller K; Hadji P; Hahn A
Nutr Res; 2016 Oct; 36(10):1162-1170. PubMed ID: 27865358
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
35. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
[TBL] [Abstract][Full Text] [Related]
37. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial.
Asztalos IB; Gleason JA; Sever S; Gedik R; Asztalos BF; Horvath KV; Dansinger ML; Lamon-Fava S; Schaefer EJ
Metabolism; 2016 Nov; 65(11):1636-1645. PubMed ID: 27733252
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
[TBL] [Abstract][Full Text] [Related]
39. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
Liu CS; Lii CK; Chang LL; Kuo CL; Cheng WL; Su SL; Tsai CW; Chen HW
Nutr Res; 2010 Feb; 30(2):118-24. PubMed ID: 20226997
[TBL] [Abstract][Full Text] [Related]
40. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
Maki KC; Dicklin MR; Davidson MH; Doyle RT; Ballantyne CM;
Am J Cardiol; 2010 May; 105(10):1409-12. PubMed ID: 20451686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]